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lay people, particularly people in the press, fre-
quently ask the question “When will we cure cancer?” 
I believe that we will never cure cancer.
For an organism like a human being, which begins 
as one cell and, in the adult phase, averages 70 trillion 
(70,000,000,000,000) cells, with these cells continu-
ously dying and being replaced, it is apparent that 
this mind-boggling rate of reproduction will almost 
certainly have errors. We know that cancer is strongly 
associated with age—that is, the longer an organism 
lives, the higher the probability that a malignancy will 
develop—and the theoretic basis for this fact is that 
it takes multiple events to initiate a malignancy. We 
also know that patients with a diagnosed cancer that 
is eliminated or cured are at substantially increased 
risk for developing another malignancy. again, theo-
retically, because one “hit” has already occurred, a 
second “hit” that might not initiate a cancer in an 
otherwise normal person could initiate a cancer in a 
patient who has had a previous cancer.
Thus, as we prolong life, the greater is the likeli-
hood of a malignancy developing. and so one has 
to reach the conclusion that cancer, as an umbrella 
term for a large group of malignancies, will always 
be present and will never be eradicated in the same 
sense that polio or smallpox can be eradicated. rather, 
the malignancies that occur can be cured, and con-
sequently life will be prolonged and cancer will be 
considered controlled, particularly if other events 
such as other diseases or accidents or homicide or 
suicide terminate people’s lives.
a very important concept that is highly popular 
with lay people, and particularly with politicians, is 
that the way to control cancer or even to eliminate it 
is to use the current methods of early detection. The 
hypothesis that early detection is a technique for 
controlling cancer is based entirely on the Halstedian 
hypothesis that cancer begins in a site, spreads region-
ally, and then spreads systemically. Unfortunately, 
when tested, this hypothesis has always failed, as 
shown most conclusively in studies of therapy for 
breast cancer1. The application of more and more 
radical surgery does not in fact increase the cure rate 
of diseases such as breast cancer, prostate cancer, and 
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so on, as is dramatically demonstrated by the data 
that have been carefully summarized in an important 
book titled Should I Be Tested for Cancer? That book 
demonstrates that the early detection model simply 
inclines to lead-time bias and recognition of abnor-
malities that would never become systemic cancer2. 
The latter statement is even more strongly supported 
by the fact that, for diseases for which excellent early 
detection techniques are available, such as breast 
cancer and prostate cancer, the incidence of cancer 
in developed countries is very much higher than it 
is in countries such as africa, eastern Europe, and 
Micro-Polynesia. Yet the mortality in those areas is 
comparable to the mortality in North america3. One 
therefore has to conclude that the early detection 
model will not control cancer, but simply increase the 
incidence of cancer in addition to introducing very 
powerful lead-time bias.
Everyone is willing to concede that prevention 
could be an effective strategy for eliminating can-
cer. Certainly, eliminating the three most important 
proven carcinogens—tobacco, ultraviolet exposure, 
and alcohol—is certainly effective in reducing the 
frequency of cancer. Yet, more than 50 years ago, it 
was conclusively shown that smoking is responsible 
for a great preponderance of human lung cancer, and 
although we have been slightly successful in reducing 
smoking practices in the male population, the reduc-
tion approach has been frustratingly ineffective in 
the female population, in which smoking continues 
to increase. But it has been observed in male popula-
tions that the proportion of patients who are smokers 
among those diagnosed with lung cancer continues 
to decrease. Clearly, then, tobacco as a carcinogen 
is a promoting agent and not an initiating agent for 
lung cancer.
The illusion that further research on prevention 
or early detection will eliminate cancer is just not 
compatible with the science and the facts that we 
have at hand. What is obvious is that, to control 
cancer, we will have to learn to control advanced 
cancer—that is, systemic metastatic cancer. That 
disease is the cause of morbidity and mortality, 
and if we are going to control systemic cancer, 2
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I contend that we should focus our attention on 
leukemia. Given that leukemia is a systemic disease 
in every patient, we do not have to deal with the 
local–regional–systemic hypothesis that involves 
surgery, radiation, and modalities that are designed 
to control local disease and to prevent metastatic 
disease. leukemia is not helped by surgery or radia-
tion, and local control plays no role. So we have to 
study the systemic form of leukemia from the outset. 
Even more important is the fact that leukemia is 
much more accessible to the scientific community 
than any other form of malignancy. The cancer cells 
are in the blood and in the bone marrow, and both 
of these organs can be sampled repeatedly with 
enormous quantities of material, so that questions 
of biology can be addressed in the laboratory. Even 
more important is the fact that human leukemia cell 
lines have been established and many more are be-
ing established every day: one can study the entire 
malignant process in vitro, and transplants of human 
leukemia into experimental animals allow for the 
study of leukemic cells in vivo in those animals.
Finally, and perhaps most important, dramatic 
progress has been made in the control of leukemia 
over the last 60 years: the discovery of combination 
chemotherapy, the discovery of adjuvant chemo-
therapy, the discovery of neoadjuvant chemotherapy 
(that is, systemic therapy before local therapy for 
localized tumours), the discovery of the genetic basis 
of leukemia (the chromosome abnormalities, the mo-
lecular abnormalities). Most important is the fact that, 
for childhood acute lymphoblastic leukemia, 85% 
of patients achieve long-term survival—more than 
5 years. adults with acute lymphoblastic leukemia 
are increasingly benefiting from therapy, and 20% of 
patients with acute myeloblastic leukemia experience 
survival in excess of 5 years. Patients with chronic 
granulocytic leukemia have seen their disease totally 
transformed—from one that was 100% fatal, with 
median survival of 3.5 years, to a circumstance in 
which more than 90% are free of disease at 10 years 
as the result of a therapy in which a pill is taken 
orally. In chronic lymphocytic leukemia, there has 
been a dramatic improvement in treatment that not 
only controls the disease, but extends survival. For 
the other leukemic disorders—the myeloprolifera-
tive diseases and the myelodysplastic diseases-again, 
enormous advances in understanding and treatment 
have occurred in the last five years. Much of this 
advancement has been extensively reviewed in the 
literature and need not be reviewed here.
In sum, I believe that control of cancer as a public 
health problem will result not from early detection, 
but from control of systemic, metastatic disease. 
leukemia is an excellent model for understanding hu-
man metastatic disease, and the progress that has been 
made in the control of leukemia has been immediately 
applicable to the other, more common solid tumours 
in humans. We should therefore increasingly focus 
our scientific efforts on controlling human leukemia 
as the best strategy for controlling cancer as a major 
public health problem.
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